Intercept Drug Patent Portfolio
Intercept owns 1 orange book drug protected by 10 US patents Given below is the list of Intercept's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10052337 | Compositions of obeticholic acid and methods of use | 26 Apr, 2036 | Active |
| US10751349 | Compositions of obeticholic acid and methods of use | 26 Apr, 2036 | Active |
| US10758549 | Compositions of obeticholic acid and methods of use | 26 Apr, 2036 | Active |
| US10047117 | Preparation and uses of obeticholic acid | 06 Sep, 2033 | Active |
| US10174073 | Preparation and uses of obeticholic acid | 17 Jun, 2033 | Active |
| US9238673 | Preparation and uses of obeticholic acid | 17 Jun, 2033 | Active |
| USRE48286 | Steroids as agonists for FXR | 21 Feb, 2027 | Active |
| US7138390 | Steroids as agonists for FXR | 16 Nov, 2022 | Expired |
| US8058267 | Steroids as agonists for FXR | 21 Feb, 2022 | Expired |
| US8377916 | Steroids as agonists for FXR | 21 Feb, 2022 | Expired |
Latest Legal Activities on Intercept's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Intercept.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Mar, 2024 | US10758549 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Feb, 2024 | US10751349 |
|
Expire Patent
Critical
| 18 Dec, 2023 | US8058267 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jul, 2023 | US9238673 |
|
Maintenance Fee Reminder Mailed
Critical
| 03 Jul, 2023 | US8058267 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Jul, 2022 | US10174073 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Feb, 2022 | US10052337 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2022 | US10047117 |
| Mail-Petition Decision - Granted | 06 Nov, 2020 | US7138390 |
|
Petition Decision - Granted
Critical
| 05 Nov, 2020 | US7138390 |
| Petition Entered | 28 Oct, 2020 | US7138390 |
|
Recordation of Patent Grant Mailed
Critical
| 01 Sep, 2020 | US10758549 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 01 Sep, 2020 | US10758549 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 25 Aug, 2020 | US10751349 |
|
Recordation of Patent Grant Mailed
Critical
| 25 Aug, 2020 | US10751349 |
Intercept's Family Patents
Intercept drugs have patent protection in a total of 38 countries. It's US patent count contributes only to 23.2% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Intercept Drug List
Given below is the complete list of Intercept's drugs and the patents protecting them.
1. Ocaliva
Ocaliva is protected by 10 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10052337 | Compositions of obeticholic acid and methods of use |
26 Apr, 2036
(10 years from now)
| Active |
| US10751349 | Compositions of obeticholic acid and methods of use |
26 Apr, 2036
(10 years from now)
| Active |
| US10758549 | Compositions of obeticholic acid and methods of use |
26 Apr, 2036
(10 years from now)
| Active |
| US10047117 | Preparation and uses of obeticholic acid |
06 Sep, 2033
(7 years from now)
| Active |
| US10174073 | Preparation and uses of obeticholic acid |
17 Jun, 2033
(7 years from now)
| Active |
| US9238673 | Preparation and uses of obeticholic acid |
17 Jun, 2033
(7 years from now)
| Active |
| USRE48286 | Steroids as agonists for FXR |
21 Feb, 2027
(1 year, 1 month from now)
| Active |
| US7138390 | Steroids as agonists for FXR |
16 Nov, 2022
(3 years ago)
| Expired |
| US8058267 | Steroids as agonists for FXR |
21 Feb, 2022
(3 years ago)
| Expired |
| US8377916 | Steroids as agonists for FXR |
21 Feb, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ocaliva's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List